Daniel Eriksson

机构：Uppsala University, Sustainable Business Hub (Sweden) · ORCID：0000-0001-7699-242X

发表论文 52 篇 · 总被引 826 次 · h-index 14

代表论文

Rivaroxaban vs. warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes (2019 · European Heart Journal - Quality of Care and Clinical Outcomes · 被引 67)
Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non‐valvular atrial fibrillation and type 2 diabetes (2019 · Diabetes Obesity and Metabolism · 被引 45)
Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease (2019 · European Heart Journal - Cardiovascular Pharmacotherapy · 被引 30)
Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries (2023 · Advances in Therapy · 被引 11)
Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment (2019 · Cardiology Research and Practice · 被引 11)
Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study) (2023 · Hematology · 被引 9)